# Phosphatases in tumor cell immune escape: a perspective based on the camouflage, coercion, cytoprotection

## TL;DR

This paper explores how protein phosphatases help tumor cells avoid the immune system, offering new insights for cancer immunotherapy.

## Contribution

The paper introduces the novel 'three Cs' framework (camouflage, coercion, cytoprotection) to explain phosphatase roles in tumor immune evasion.

## Key findings

- Protein phosphatases act as dynamic molecular switches in tumor immune evasion.
- Phosphatases regulate tumor cell evasion across recognition, immune cell inhibition, and resistance to immune attacks.
- Targeting phosphatase networks could overcome drug resistance in immunotherapies.

## Abstract

Tumor immune evasion represents a core challenge restricting the efficacy of cancer treatment, and a deep understanding of its underlying mechanisms is crucial for developing novel immunotherapeutic approaches. This article focuses on the multidimensional regulatory roles of protein phosphatases in this critical biological process, innovatively adopting the “three Cs” framework—camouflage, coercion, and cytoprotection—for systematic elaboration, thereby revealing phosphatases as core molecular switches within dynamic regulatory networks. Our review systematically demonstrates that protein phosphatases serve as indispensable “dynamic molecular switches” within the “three Cs” framework of tumor immune evasion. Their regulatory networks span the entire continuum of tumor cells evading recognition, inhibiting immune cell function, and resisting terminal immune attacks. This insight underscores the substantial potential of targeting phosphatase regulatory networks, which may overcome the drug resistance bottleneck encountered in current immunotherapies. By designing novel drug strategies to precisely intervene in key phosphatase nodes—thereby achieving “one target, multiple effects” synergistic regulation—this framework provides a robust theoretical foundation and promising new avenues for developing more efficient, broad-spectrum next-generation tumor immunotherapies.